Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 14/20 | 0.65 |
| ▸ | JAK1 | P23458 | 12/20 | 0.65 |
| ▸ | JAK2 | O60674 | 11/20 | 0.57 |
| ▸ | TYK2 | P29597 | 4/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.50 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26361468 | 0.95 | JAK3 (0.60) | JAK3JAK1JAK2TYK2LRRK2 | |
| SCHEMBL24258095 | 0.93 | JAK3 (0.57) | JAK3JAK1JAK2TYK2LRRK2 | |
| SCHEMBL15071983 | 0.88 | JAK2 (0.58) | JAK3JAK1JAK2TYK2TNK2 | |
| SCHEMBL22272079 | 0.81 | JAK3 (0.74) | JAK3JAK1JAK2TYK2LRRK2 | |
| SCHEMBL17209868 | 0.79 | JAK3 (0.60) | JAK3JAK1JAK2TYK2LRRK2 | |
| SCHEMBL20844425 | 0.79 | JAK3 (1.00) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL24258131 | 0.79 | TNK2 (0.53) | JAK3JAK2TYK2LRRK2TNK2 | |
| SCHEMBL15059873 | 0.77 | CDK19 (0.58) | JAK3JAK1JAK2TYK2 | |
| SCHEMBL24258127 | 0.76 | TNK2 (0.55) | JAK2TYK2LRRK2TNK2 | |
| SCHEMBL27059234 | 0.76 | LRRK2 (0.57) | JAK3JAK1JAK2TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-28 | — | — | US | disclosed |
| WO-2022036310-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | JAK3 500/4885JAK1 594/4885JAK2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.